New combination therapy clinical trial opens for patients with metastatic or unresectable solid tumors


Metastatic tumors are tumors that have spread from their original site to form tumors in other parts of the body, and unresectable tumors cannot be removed by surgery.  A study of a new drug combination for patients with metastatic and unresectable solid tumors uses Liposomal irinotecan, an anticancer drug that circulates longer in the body, and Veliparib, which kills cancer cells by blocking a protein they need to repair themselves. Anish Thomas, M.D., of the Developmental Therapeutics Branch is leading this trial that tests the combination of intravenous irinotecan and oral veliparib to study any side effects and best dose of this drug combination. For more information about this trial, please visit:  https://ccr.cancer.gov/Developmental-Therapeutics-Branch/anish-thomas?qt-staff_profile_tabs=0#qt-staff_profile_tabs.

To view all CCR clinical trials, please visit: https://ccr.cancer.gov/clinical-trials.

Summary Posted: 06/2017